Atea Pharmaceuticals' rejection of the unsolicited proposal from Tang Capital Partners on behalf of Concerta Biosciences has led to a decrease in its share price. Investors may perceive this rejection as a missed opportunity for growth or collaboration, causing a negative impact on the stock price in the short term.